Español
The Oligofastx project covers the different phases of the development of oligonucleotide-based therapies, from design to production, and this is one of the reasons why the consortium is made up of seven companies, each specializing in different phases of the process. Today we talk about solid-phase synthesis. Oligonucleotides are short chains of different “building blocks” […]
Author Archives: oligofastx
25
Nov
Nov
OLIGOFASTX follows with great interest all the recent advances in the work with oligonucleotides, not only in terms of new lines of research, but also with respect to all the applications that are being developed close to the market. Because it is our ultimate goal and our objective: to provide solutions to diseases that do […]
07
Nov
Nov
History is peppered with stories, legends and tales. And as in all of them, any biography of a person of international relevance, such as the one we are dealing with today, is full of anecdotes, joys and sorrows and betrayals. Recognizing all his valuable contributions, the life of Maurice Wilkins is marked by destiny: the […]
26
Oct
Oct
Thyroid cancer is a common malignancy of the endocrine system. There are four types: Papillary thyroid cancer is the most common of all thyroid cancers. Follicular thyroid cancer accounts for 10% of thyroid cancers. Medullary thyroid cancer represents 2% of thyroid cancers. Anaplastic thyroid cancer is the most advanced and aggressive of the thyroid cancers. […]
20
Oct
Oct
Today we are going to talk about one of those diseases classified as rare, for which there is, as yet, no solution. It is one of the diseases we are working on and researching at Oligofastx: Guillain-Barré syndrome. Guillain-Barré syndrome (GBS) is a neurological disorder in which the body’s immune system attacks the peripheral nervous […]
Nobel Prize
The Most Excellent Nobel Laureates 2022: these were the winners in the categories of Chemistry and Medicine
06
Oct
Oct
The work of the most renowned scientists, artists and diplomats is rewarded every year at this time thanks to the Nobel Prizes. And the whole of society, but especially the scientific community, is always on the lookout to find out who wins such a distinguished title. Once again this year, we congratulate ourselves for the […]
26
Sep
Sep
Every last Sunday of September is celebrated the International Retinitis Pigmentosa Day, one of the rare and genetic diseases of the retina. Aware of the complications that the disease can bring, from Oligofastx we work together in the research and development of solutions based on the development of oligonucleotides to reach an effective treatment. This […]
15
Sep
Sep
Today is International Myotonic Dystrophy Day, a rare disease with no treatment or cure to date. Although Myotonic Dystrophy is not within the Oligofastx project, it is one of the diseases on which Arthex Biotech (Oligofastx partner company) is researching and working to find a therapeutic solution. Specifically, Arthex is developing an experimental RNA-based drug […]